CLABF (Core One Labs) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Core One Labs FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Core One Labs's Free Cash Flow for the three months ended in Dec. 2023 was $0.00 Mil. Core One Labs's Revenue for the three months ended in Dec. 2023 was $0.07 Mil. Therefore, Core One Labs's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Core One Labs's current FCF Yield % is -8.17%.

The historical rank and industry rank for Core One Labs's FCF Margin % or its related term are showing as below:

CLABF' s FCF Margin % Range Over the Past 10 Years
Min: -6816.23 Med: -1984.48 Max: -306.56
Current: -306.56

During the past 11 years, the highest FCF Margin % of Core One Labs was -306.56%. The lowest was -6816.23%. And the median was -1984.48%.

CLABF's FCF Margin % is ranked worse than
60.57% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs CLABF: -306.56

Core One Labs FCF Margin % Historical Data

The historical data trend for Core One Labs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs FCF Margin % Chart

Core One Labs Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

-6,797.33

-412.68

-1,075.15

Core One Labs Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-226.42	-288.24	-190.82	-	-

Competitive Comparison of Core One Labs's FCF Margin %

For the Biotechnology subindustry, Core One Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Core One Labs's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Core One Labs's FCF Margin % falls into.

Core One Labs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Core One Labs's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-3.634	/	0.338
	=	-1,075.15 %

Core One Labs's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0.07
	=	0.00 %

Core One Labs FCF Margin % Related Terms

Thank you for viewing the detailed overview of Core One Labs's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Core One Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (OTCPK:CLABF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5

Website

https://www.core1labs.com

Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.